PCN5 Real-World Incidence and Management of Adverse Events (AE) in Patients with NON-Metastatic Castrate-Resistant Prostate Cancer Receiving Apalutamide or Enzalutamide

Authors
Category Primary study
JournalValue in Health Regional Issues
Year 2020
This article has no abstract
Epistemonikos ID: dfcf6edc11ad24c9fb204756d4b0099bb3d17681
First added on: Feb 12, 2025